Drug Trial Radar · NCT07792408
Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
148
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Mar 11, 2027
Study completion Mar 20, 2027
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Aug 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives.
Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407Drug
Tablets for Oral Administration.
LNG/EEDrug
Combination Tablets for Oral Administration.
NGM/EEDrug
Combination Tablets for Oral Administration.
NET/EEDrug
Combination Tablets for Oral Administration.
DRSP/EEDrug
Combination Tablets for Oral Administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Maximum Observed Plasma Concentration (Cmax) of LNG/EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27
- Part B (Optional): Maximum Observed Plasma Concentration (Cmax) of norelgestromin (NGMN) and norgestrel (NG) (active metabolites of NGM) and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 9 and Day 23 up to Day 31
- Part C (Optional): Maximum Observed Plasma Concentration (Cmax) of NET and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 5 and Day 19 up to Day 23
- Part D (Optional): Maximum Observed Plasma Concentration (Cmax) of DRSP and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27
- Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of LNG/EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27
- Part B (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of norelgestromin (NGMN) and norgestrel (NG) (active metabolites of NGM) and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 9 and Day 23 up to Day 31
- Part C (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of NET and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 5 and Day 19 up to Day 23
- Part D (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of DRSP and EE in the Absence and Presence of VX-407Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Altasciences - Beaumont Clinic Montreal
Montreal, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.